VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
EVO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
EVOEvotec SE
$2.80$995M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksEVOFinancials

Evotec SE (EVO) Financials

23Y historyFree accessUpdated daily

Revenue volatility and structural margin compression are evident, with gross margins plummeting to -1.0% in 2026Q1 from a 31.0% peak in 2025Q4.

EVO Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03
Sales/Revenue745.24M757.26M796.97M781.43M751.45M618.03M500.92M446.44M375.4M257.63M164.51M127.68M89.5M85.94M87.27M80.13M55.26M42.68M39.61M32.88M67.35M64.11M1.94M3.57M
Revenue Growth %-5.45%-4.98%1.99%3.99%21.59%23.38%12.2%18.92%45.71%56.61%28.85%42.66%4.14%-1.52%8.91%45%29.47%7.75%20.46%-51.18%5.05%3211.02%-45.81%-
Cost of Goods Sold660.57M694.6M682.09M606.38M577.38M466.49M375.18M313.55M263.39M175.06M105.95M89.69M60.12M54.72M56.24M45.14M30.92M24.26M21.98M24.86M44.4M42.99M00
COGS % of Revenue-91.73%85.59%77.6%76.84%75.48%74.9%70.23%70.16%67.95%64.41%70.25%67.17%63.67%64.45%56.34%55.94%56.84%55.48%75.6%65.92%67.05%--
Gross Profit84.67M62.66M114.88M175.05M174.06M151.54M125.74M132.89M112.02M82.57M58.55M37.99M29.38M31.22M31.02M34.98M24.35M18.42M17.64M8.02M22.95M21.13M1.94M3.57M
Gross Margin %11.36%8.27%14.41%22.4%23.16%24.52%25.1%29.77%29.84%32.05%35.59%29.75%32.83%36.33%35.55%43.66%44.06%43.16%44.52%24.4%34.08%32.95%100%100%
Gross Profit Growth %--45.45%-34.37%0.57%14.86%20.52%-5.38%18.64%35.67%41.01%54.14%29.3%-5.91%0.64%-11.32%43.7%32.16%4.45%119.82%-65.04%8.63%991.09%-45.81%-
Operating Expenses189.23M197.97M257.4M222.56M153.22M110.55M77.19M58.38M49.22M43.89M21.81M40.52M27.24M27.05M30.72M30.65M27.17M38.03M63.13M57.24M53.75M36.26M-32.2M-36.72M
OpEx % of Revenue-26.14%32.3%28.48%20.39%17.89%15.41%13.08%13.11%17.04%13.26%31.74%30.43%31.48%35.2%38.25%49.16%89.11%159.37%174.05%79.8%56.55%-1662.82%-1027.8%
Selling, General & Admin172.36M123.65M188.2M169.61M156.19M105.44M77.2M66.43M57.01M42.38M27.01M25.17M17.99M16.6M16.3M15.76M15.96M16.7M19.95M17.81M18.58M15.54M6.1M5.27M
SG&A % of Revenue-16.33%23.61%21.71%20.79%17.06%15.41%14.88%15.19%16.45%16.42%19.71%20.1%19.31%18.68%19.67%28.87%39.11%50.36%54.15%27.58%24.24%315.05%147.49%
Research & Development36.91M74.33M50.86M68.53M76.64M65.7M59.61M58.43M35.62M17.61M18.11M18.34M12.4M9.66M8.34M8.44M6.12M20.95M42.54M36.94M30.31M9.3M00
R&D % of Revenue-9.82%6.38%8.77%10.2%10.63%11.9%13.09%9.49%6.84%11.01%14.37%13.86%11.25%9.56%10.53%11.07%49.08%107.38%112.32%45%14.51%--
Other Operating Expenses-2M018.34M-15.58M-79.62M-60.6M-59.63M-66.6M257K-209K4K263K39K16K171K1.49M1.8M-3.29M-11.87M149K274K614K-38.3M-41.99M
Operating Income-104.57M-135.31M-142.52M-47.51M20.85M41M48.56M62.59M77.46M37.49M31.34M11.64M-6.38M-21.35M-3.2M5.21M1.72M-42.3M-73.21M-58.12M-36.76M-32.97M-30.26M-33.15M
Operating Margin %-14.03%-17.87%-17.88%-6.08%2.77%6.63%9.69%14.02%20.63%14.55%19.05%9.12%-7.13%-24.84%-3.67%6.5%3.1%-99.1%-184.81%-176.72%-54.58%-51.42%-1562.82%-927.8%
Operating Income Growth %-5.06%-200%-327.85%-49.14%-15.57%-22.43%-19.2%106.6%19.63%169.26%282.42%70.11%-566.8%-161.49%203.62%104.05%42.22%-25.97%-58.08%-11.52%-8.93%8.71%-
EBITDA-41.11M-39.76M-40.9M45.47M104.05M111.39M104.61M111.4M108.76M58.26M43.23M23.58M2.15M-12.19M5.61M11.81M7.22M-37.52M-68.08M-49.17M-27.15M-16.57M-28.12M-31.12M
EBITDA Margin %-5.52%-5.25%-5.13%5.82%13.85%18.02%20.88%24.95%28.97%22.61%26.28%18.47%2.41%-14.18%6.43%14.75%13.07%-87.91%-171.88%-149.53%-40.31%-25.84%-1452.23%-870.96%
EBITDA Growth %70.72%2.79%-189.95%-56.3%-6.6%6.48%-6.09%2.43%86.67%34.75%83.35%994.25%117.68%-317.06%-52.48%63.6%119.25%44.89%-38.46%-81.12%-63.89%41.09%9.64%-
D&A (Non-Cash Add-back)73.11M95.55M101.62M92.98M83.2M70.4M56.06M48.81M31.29M20.77M11.89M11.94M8.54M9.16M8.82M6.61M5.51M4.78M5.13M8.94M9.61M16.4M2.14M2.03M
EBIT-112.68M-135.31M-182.28M-68.85M-140.81M246.23M34.3M37.96M74.59M26.83M34.47M14.22M-4.71M-23.23M-4.31M7.11M4.73M-44.39M-75.13M-14.82M-33.09M-34.83M-30.26M-33.15M
Net Interest Income-9.61M-9.62M-9.26M-2.48M-4.81M-6.98M-7.13M-5.22M-1.69M-358K-660K-1.19M-1.15M-1.61M-1.2M-1.45M-625K66K2.12M1.57M698K153K00
Interest Income5.02M4.25M2.44M9.26M8.34M2.27M1.34M2.23M898K903K863K533K469K261K655K413K241K499K2.96M1.96M1.37M851K00
Interest Expense14.63M13.87M11.7M11.74M13.15M9.25M8.46M7.46M2.59M1.26M1.52M1.73M1.62M1.87M1.86M1.86M866K433K839K483K671K698K00
Other Income/Expense-76.81M12M-51.45M-33.09M-174.81M195.98M-22.72M-6.03M-5.46M-11.16M1.61M851K1.22M-2.3M-6.54M49K2.15M-21.16M-28.2M1.37M-1.46M-20.4M00
Pretax Income-181.38M-123.31M-193.98M-80.59M-153.96M236.98M25.84M56.56M72M26.33M32.95M12.49M-5.16M-23.65M-5.01M5.26M3.87M-44.82M-75.97M-54.41M-35.98M-35.53M00
Pretax Margin %-24.34%-16.28%-24.34%-10.31%-20.49%38.34%5.16%12.67%19.18%10.22%20.03%9.78%-5.76%-27.52%-5.75%6.56%7%-105%-191.78%-165.44%-53.41%-55.42%--
Income Tax14.64M-23.88M2.1M3.32M21.7M21.47M19.56M19.33M-12.06M2.33M6.11M-4.03M1.82M1.78M-7.49M-1.4M882K678K2.32M-6.35M320K-4.53M-798.91K96.08K
Effective Tax Rate %-8.07%19.37%-1.08%-4.12%-14.09%9.06%75.7%34.18%-16.75%8.86%18.55%-32.22%-35.26%-7.55%149.42%-26.54%22.81%-1.51%-3.05%11.68%-0.89%12.74%--
Net Income-196.02M-99.43M-196.08M-83.91M-175.66M215.51M6.28M38.16M84.17M24.26M27.53M16.52M-6.98M-25.43M2.48M6.75M3.26M-45.5M-78.29M-11.16M-32.47M-33.58M-29.46M-33.25M
Net Margin %-26.3%-13.13%-24.6%-10.74%-23.38%34.87%1.25%8.55%22.42%9.42%16.73%12.94%-7.8%-29.59%2.84%8.42%5.9%-106.59%-197.63%-33.92%-48.2%-52.38%-1521.56%-930.49%
Net Income Growth %5.3%49.29%-133.67%52.23%-181.51%3332.78%-83.55%-54.67%247%-11.89%66.69%336.69%72.56%-1126.35%-63.28%107.02%107.17%41.88%-601.75%65.64%3.32%-13.98%11.38%-
Net Income (Continuing)-196.02M-99.43M-196.08M-83.91M-175.66M215.51M6.28M37.31M84.06M25M27.21M16.52M-6.98M-25.43M2.48M6.65M2.98M-45.5M-78.29M-48.05M-36.3M-31M-29.46M-33.25M
Discontinued Operations000000000000000000000000
Minority Interest00000000876K992K901K1.59M0000476K613K00-6K000
EPS (Diluted)-0.55-0.28-0.56-0.23-0.490.650.020.130.280.080.100.06-0.03-0.100.010.030.02-0.21-0.41-0.08-0.56-0.62-0.68-18.50
EPS Growth %5.31%50%-143.48%53.06%-175.38%3150%-84.62%-53.57%250%-20%66.67%326.42%73.5%-1100%-66.67%100%107.14%48.78%-412.5%85.71%9.68%8.82%96.32%-
EPS (Basic)--0.28-0.56-0.23-0.490.650.020.130.280.080.100.07-0.03-0.100.010.030.02-0.21-0.41-0.08-0.56-0.62-0.68-18.50
Diluted Shares Outstanding355.12M355.16M354.59M353.87M353.41M332.81M307.5M299.45M294.96M290.02M265.01M275.27M262.58M242.43M234.59M232.04M218.03M213.69M190.4M143.66M58.69M53.78M43.41M1.8M
Basic Shares Outstanding355.12M355.16M353.29M353.87M353.35M332.81M307.5M299.45M294.96M290.02M265.01M263.36M262.58M242.43M234.59M232.04M218.03M213.69M190.4M143.66M58.69M53.74M43.41M1.8M
Dividend Payout Ratio-----------3.34%--121.07%-11.75%-------

Key Metrics

Growth RegimeDecelerating
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

High Operating Leverage Sensitivity

Revenue Volatility Masks Structural Stagnation

As evidenced by the most recent quarterly data, Evotec's revenue contracted by 20.4% year-over-year in 2026Q1, highlighting the inherent instability of a business model heavily reliant on non-recurring milestone payments rather than consistent, organic service-based growth across its core EVT Execute and Innovate segments.

The sharp revenue decline suggests that the company's reliance on project-based milestones creates significant top-line unpredictability. Investors should monitor whether this contraction reflects a broader cyclical downturn in biotech R&D spending or a specific loss of momentum in the company's partnered pipeline.

Structural Margin Compression Remains Persistent

Based on reported financial statements, Evotec's gross margin plummeted to -1.0% in 2026Q1, a stark departure from the 31.0% peak observed in 2025Q4, indicating that the company's high fixed-cost infrastructure is failing to achieve the necessary scale to support profitable operations.

The extreme volatility in gross margins suggests that the company's J.POD facilities and specialized laboratory assets are highly sensitive to utilization rates. This lack of margin stability implies that the current cost structure may be fundamentally misaligned with the company's ability to generate consistent, high-margin revenue.

Operating Leverage Remains Deeply Negative

According to recent SEC filings, Evotec reported an operating margin of -35.4% in 2026Q1, demonstrating that the company's administrative and research overhead continues to outpace its ability to generate gross profit, thereby preventing any meaningful path toward operational self-sufficiency in the near term.

The persistent negative operating income suggests that the company's SG&A and R&D expenses are not scaling efficiently with revenue. This trend warrants further investigation into whether management can implement sufficient cost-discipline measures to offset the high fixed-cost burden inherent in their platform model.

Sustainability of the Platform Model

Based on the provided income statement data, the recurring inability to maintain positive operating margins suggests that the company's 'End-to-End' platform may be structurally over-capitalized, raising concerns about the long-term viability of its current business model without significant and sustained external capital injections.

Short-sellers would likely focus on the widening gap between revenue generation and operational costs, which appears to be accelerating rather than narrowing. The reliance on milestone-driven income creates a precarious financial profile that may struggle to survive prolonged periods of industry-wide R&D budget tightening.

EVO — Frequently Asked Questions

Quick answers to the most common questions about buying EVO stock.

What was Evotec SE's (EVO) revenue in 2025?

For fiscal year 2025, Evotec SE (EVO) reported total revenue of $757.3M. This represents a 21093.1% increase compared to $3.6M in 2003.

Is Evotec SE (EVO) profitable?

Evotec SE (EVO) reported a net loss of $99.4M for the fiscal year ending 2025.

What is Evotec SE's operating profit margin?

Evotec SE (EVO) reported an operating income of $-135.3M, resulting in an operating profit margin of -17.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Evotec SE's gross profit and gross margin?

Evotec SE (EVO) generated $62.7M in gross profit for the year, representing a gross profit margin of 8.3%. This demonstrates the company's core pricing power and production efficiency.